A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of
relapsing remitting multiple sclerosis, comparing two doses versus placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Neurotec Pharma
Collaborator:
Advancell - Advanced In Vitro Cell Technologies, S.A.